Biogen Inc. (BIIB) Shares Bought by GMT Capital Corp
GMT Capital Corp grew its holdings in Biogen Inc. (NASDAQ:BIIB) by 16.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 293,100 shares of the biotechnology company’s stock after buying an additional 40,900 shares during the quarter. Biogen makes up about 2.0% of GMT Capital Corp’s investment portfolio, making the stock its 14th largest holding. GMT Capital Corp owned approximately 0.14% of Biogen worth $91,775,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. purchased a new stake in Biogen in the 3rd quarter worth approximately $123,494,000. Botty Investors LLC lifted its holdings in Biogen by 75.0% in the 2nd quarter. Botty Investors LLC now owns 11,232 shares of the biotechnology company’s stock worth $3,048,000 after buying an additional 4,812 shares during the period. BB&T Securities LLC lifted its holdings in Biogen by 25.0% in the 2nd quarter. BB&T Securities LLC now owns 12,989 shares of the biotechnology company’s stock worth $3,524,000 after buying an additional 2,598 shares during the period. Neuberger Berman Group LLC lifted its holdings in Biogen by 18.6% in the 2nd quarter. Neuberger Berman Group LLC now owns 27,974 shares of the biotechnology company’s stock worth $7,591,000 after buying an additional 4,389 shares during the period. Finally, Pacer Advisors Inc. lifted its holdings in Biogen by 10.5% in the 2nd quarter. Pacer Advisors Inc. now owns 7,028 shares of the biotechnology company’s stock worth $1,907,000 after buying an additional 667 shares during the period. Institutional investors and hedge funds own 88.28% of the company’s stock.
Biogen Inc. (NASDAQ:BIIB) opened at $309.80 on Friday. The stock has a market capitalization of $65,515.54, a price-to-earnings ratio of 14.35, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. Biogen Inc. has a one year low of $244.28 and a one year high of $348.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.19.
Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.70 by $0.61. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.19 earnings per share. equities research analysts forecast that Biogen Inc. will post 22.03 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/11/24/biogen-inc-biib-shares-bought-by-gmt-capital-corp.html.
Several equities research analysts have weighed in on the company. Goldman Sachs Group, Inc. (The) upgraded Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price objective for the company in a report on Wednesday, August 16th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $350.00 price objective on shares of Biogen in a report on Wednesday. Mizuho reiterated a “neutral” rating and issued a $319.00 price objective (up previously from $274.00) on shares of Biogen in a report on Wednesday, September 13th. BidaskClub upgraded Biogen from a “hold” rating to a “buy” rating in a research note on Friday, August 4th. Finally, SunTrust Banks, Inc. began coverage on Biogen in a research note on Wednesday, September 20th. They issued a “buy” rating and a $360.00 target price for the company. Twelve analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $341.89.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.